The Evolving Treatment Landscape of Follicular Lymphoma: Focus on BTK Inhibition

Hear Christopher Flowers, a leading clinician in B-cell malignancies, for an update in the treatment of follicular lymphoma. Dr Flowers reviews the pivotal ROSEWOOD data for the BTK inhibitor zanubrutinib in the treatment of relapsed/refractory follicular lymphoma and discusses potential implications on patient care.

Program Content

Activities

  • Focus on BTK Inhibition
    The Evolving Treatment Landscape of Follicular Lymphoma: Focus on BTK Inhibition
    Video
    Congratulations: You achieved a completion on 04/09/2022

    Released: April 10, 2024

    Expires: July 30, 2024

Faculty

cover img faculity

Christopher R. Flowers, MD, MS

Department Chair
Department of Lymphoma/Myeloma, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas